ASP Isotopes Inc. (NASDAQ:ASPI) Stock Holdings Lifted by Nuveen Asset Management LLC

Nuveen Asset Management LLC raised its stake in shares of ASP Isotopes Inc. (NASDAQ:ASPI - Free Report) by 672.1% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 413,346 shares of the company's stock after acquiring an additional 359,811 shares during the period. Nuveen Asset Management LLC owned approximately 0.58% of ASP Isotopes worth $1,872,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. JPMorgan Chase & Co. increased its position in ASP Isotopes by 31.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 22,196 shares of the company's stock valued at $62,000 after purchasing an additional 5,307 shares during the period. SG Americas Securities LLC acquired a new stake in shares of ASP Isotopes in the fourth quarter valued at $100,000. Almanack Investment Partners LLC. acquired a new stake in ASP Isotopes in the fourth quarter valued at approximately $68,000. Rhumbline Advisers grew its position in shares of ASP Isotopes by 69.1% during the fourth quarter. Rhumbline Advisers now owns 60,363 shares of the company's stock worth $273,000 after acquiring an additional 24,664 shares during the last quarter. Finally, Boston Financial Mangement LLC acquired a new stake in shares of ASP Isotopes in the 4th quarter valued at approximately $50,000. Institutional investors own 16.80% of the company's stock.

Insiders Place Their Bets

In other ASP Isotopes news, COO Robert Ainscow sold 66,668 shares of the company's stock in a transaction dated Thursday, April 17th. The shares were sold at an average price of $5.62, for a total transaction of $374,674.16. Following the completion of the sale, the chief operating officer now directly owns 1,419,992 shares in the company, valued at $7,980,355.04. This represents a 4.48% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Paul Elliot Mann sold 316,666 shares of the stock in a transaction on Thursday, April 17th. The shares were sold at an average price of $5.62, for a total value of $1,779,662.92. Following the sale, the chief executive officer now owns 7,315,454 shares in the company, valued at approximately $41,112,851.48. This represents a 4.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 766,667 shares of company stock valued at $4,358,502. 21.40% of the stock is currently owned by company insiders.

ASP Isotopes Stock Performance

Shares of NASDAQ:ASPI traded up $0.60 on Friday, hitting $9.36. The company had a trading volume of 4,159,360 shares, compared to its average volume of 2,681,423. ASP Isotopes Inc. has a 1-year low of $1.86 and a 1-year high of $9.50. The stock has a 50 day moving average price of $6.32 and a 200 day moving average price of $5.48. The company has a current ratio of 7.55, a quick ratio of 7.54 and a debt-to-equity ratio of 0.80. The stock has a market cap of $702.58 million, a price-to-earnings ratio of -15.34 and a beta of 3.56.

Wall Street Analysts Forecast Growth

Separately, Canaccord Genuity Group upped their price target on ASP Isotopes from $8.50 to $11.00 and gave the stock a "buy" rating in a research note on Wednesday, May 21st.

ASP Isotopes Company Profile

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235.